ZA200801885B - Pyrrolopyridine derivatives and use of same as PPAR receptor modulators - Google Patents
Pyrrolopyridine derivatives and use of same as PPAR receptor modulatorsInfo
- Publication number
- ZA200801885B ZA200801885B ZA200801885A ZA200801885A ZA200801885B ZA 200801885 B ZA200801885 B ZA 200801885B ZA 200801885 A ZA200801885 A ZA 200801885A ZA 200801885 A ZA200801885 A ZA 200801885A ZA 200801885 B ZA200801885 B ZA 200801885B
- Authority
- ZA
- South Africa
- Prior art keywords
- ppar
- alkyl
- pyrrolopyridine derivatives
- same
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71345905P | 2005-09-01 | 2005-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200801885B true ZA200801885B (en) | 2009-08-26 |
Family
ID=37735036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200801885A ZA200801885B (en) | 2005-09-01 | 2006-08-31 | Pyrrolopyridine derivatives and use of same as PPAR receptor modulators |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7557122B2 (es) |
| EP (1) | EP1919474B1 (es) |
| JP (1) | JP5232000B2 (es) |
| KR (1) | KR101289589B1 (es) |
| CN (1) | CN101242833B (es) |
| AT (1) | ATE438396T1 (es) |
| AU (1) | AU2006286348B2 (es) |
| BR (1) | BRPI0615335A2 (es) |
| CA (1) | CA2620662C (es) |
| DE (1) | DE602006008320D1 (es) |
| DK (1) | DK1919474T3 (es) |
| EA (1) | EA014185B1 (es) |
| ES (1) | ES2331336T3 (es) |
| FR (1) | FR2890072A1 (es) |
| HK (1) | HK1116698A1 (es) |
| HR (1) | HRP20090512T1 (es) |
| IL (1) | IL189189A (es) |
| MX (1) | MX2008003038A (es) |
| MY (1) | MY142983A (es) |
| NO (1) | NO340681B1 (es) |
| PL (1) | PL1919474T3 (es) |
| PT (1) | PT1919474E (es) |
| SI (1) | SI1919474T1 (es) |
| TN (1) | TNSN08091A1 (es) |
| UA (1) | UA92026C2 (es) |
| WO (1) | WO2007026104A1 (es) |
| ZA (1) | ZA200801885B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2607670A1 (en) * | 2005-05-10 | 2006-11-16 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
| FR2890071B1 (fr) * | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| KR101156845B1 (ko) * | 2007-05-21 | 2012-06-18 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 헤테로시클릭 키나제 조절제 |
| FR2955108B1 (fr) * | 2010-01-08 | 2012-03-16 | Fournier Lab Sa | Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
| FR2955110A1 (fr) * | 2010-01-08 | 2011-07-15 | Fournier Lab Sa | Nouveaux derives de type pyrrolopyridine benzoique |
| WO2013122897A1 (en) * | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| GB201317363D0 (en) * | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| CN103630519A (zh) * | 2013-12-03 | 2014-03-12 | 华东理工大学 | 应用pH敏感的比率荧光蛋白检测酶-前药反应的方法 |
| CN108164528B (zh) * | 2018-03-31 | 2019-03-22 | 杭州巴洛特生物科技有限公司 | 一种酰胺类衍生物及其在高血压、高血脂和动脉粥样硬化中的应用 |
| CN108456207B (zh) * | 2018-03-31 | 2020-11-20 | 浙江药苑生物科技有限公司 | 一种酰胺类衍生物及其在心脑血管方面的应用 |
| CN108383838B (zh) * | 2018-03-31 | 2020-08-28 | 浙江药苑生物科技有限公司 | 一种酰胺类衍生物及其在高血压、高血脂和动脉粥样硬化中的应用 |
| CN108218865B (zh) * | 2018-03-31 | 2020-06-26 | 济南市儿童医院 | 一种酰胺类衍生物及其在心脑血管方面的应用 |
| CN111793066B (zh) * | 2020-07-17 | 2022-04-08 | 瀚海新拓(杭州)生物医药有限公司 | 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| ES2184145T3 (es) | 1996-12-13 | 2003-04-01 | Aventis Pharma Inc | Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida. |
| AU784722B2 (en) | 2000-02-18 | 2006-06-01 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| AU2002258550B2 (en) | 2001-03-14 | 2006-04-27 | Eli Lilly And Company | Retinoid X receptor modulators |
| CA2467542A1 (en) * | 2001-11-19 | 2003-05-30 | Neurogen Corporation | 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides |
| DE10229777A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| DE10300099A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Indol-Phenylsulfonamid-Derivate |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| NZ545326A (en) * | 2003-07-17 | 2009-12-24 | Plexxikon Inc | PPAR active compounds |
| DE10335449A1 (de) | 2003-08-02 | 2005-02-17 | Bayer Healthcare Ag | Bicyclische Indolinsulfonamid-Derivate |
| DE10335450A1 (de) | 2003-08-02 | 2005-02-17 | Bayer Ag | Indolin-Sulfanilsäureamide |
| WO2005056522A2 (en) | 2003-12-04 | 2005-06-23 | National Health Research Institutes | Indole compounds |
-
2005
- 2005-10-14 FR FR0510482A patent/FR2890072A1/fr active Pending
-
2006
- 2006-08-31 SI SI200630436T patent/SI1919474T1/sl unknown
- 2006-08-31 ZA ZA200801885A patent/ZA200801885B/xx unknown
- 2006-08-31 EP EP06808267A patent/EP1919474B1/fr active Active
- 2006-08-31 CA CA2620662A patent/CA2620662C/fr not_active Expired - Fee Related
- 2006-08-31 AU AU2006286348A patent/AU2006286348B2/en not_active Ceased
- 2006-08-31 MY MYPI20080440A patent/MY142983A/en unknown
- 2006-08-31 PT PT06808267T patent/PT1919474E/pt unknown
- 2006-08-31 CN CN2006800300423A patent/CN101242833B/zh not_active Expired - Fee Related
- 2006-08-31 WO PCT/FR2006/050827 patent/WO2007026104A1/fr active Application Filing
- 2006-08-31 KR KR1020087003832A patent/KR101289589B1/ko active IP Right Grant
- 2006-08-31 EA EA200800352A patent/EA014185B1/ru not_active IP Right Cessation
- 2006-08-31 ES ES06808267T patent/ES2331336T3/es active Active
- 2006-08-31 DE DE602006008320T patent/DE602006008320D1/de active Active
- 2006-08-31 DK DK06808267T patent/DK1919474T3/da active
- 2006-08-31 AT AT06808267T patent/ATE438396T1/de active
- 2006-08-31 PL PL06808267T patent/PL1919474T3/pl unknown
- 2006-08-31 BR BRPI0615335-6A patent/BRPI0615335A2/pt not_active Application Discontinuation
- 2006-08-31 UA UAA200802662A patent/UA92026C2/uk unknown
- 2006-08-31 MX MX2008003038A patent/MX2008003038A/es active IP Right Grant
- 2006-08-31 JP JP2008528564A patent/JP5232000B2/ja active Active
-
2008
- 2008-01-28 NO NO20080497A patent/NO340681B1/no not_active IP Right Cessation
- 2008-02-03 IL IL189189A patent/IL189189A/en not_active IP Right Cessation
- 2008-02-28 TN TNP2008000091A patent/TNSN08091A1/fr unknown
- 2008-02-29 US US12/040,336 patent/US7557122B2/en not_active Expired - Fee Related
- 2008-10-13 HK HK08111276.4A patent/HK1116698A1/xx not_active IP Right Cessation
-
2009
- 2009-06-02 US US12/476,697 patent/US7728002B2/en not_active Expired - Fee Related
- 2009-09-25 HR HR20090512T patent/HRP20090512T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189189A0 (en) | Pyrrolopyridine derivatives and use of same as ppar receptor modulators | |
| IL189183A0 (en) | Novel indole compounds | |
| MY154836A (en) | Activating agent for peroxisome prolifrator activated receptor ? | |
| DK1184366T3 (da) | Substituerede phenylpropionsyrederivater som agonister for human perioxisomproliferatoraktiveret receptor alpha(PPAR) | |
| DK1349843T3 (da) | Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer | |
| EP1690538A4 (en) | ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| WO2009064747A3 (en) | 4(-3-(-2-(phenyl) morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl) benzenesulfon amide derivatives and related compounds as modulators of ion channels for the treatment of pain | |
| NO20071319L (no) | Fremgangsmate for fremstilling av isotiazolderivater. | |
| PL378130A1 (pl) | Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń | |
| AU2003294082A1 (en) | Composition comprising a carbamic acid derivative, its use as cosmetic and medicine | |
| HRP20080187T3 (en) | Arylpiperazine derivatives and their use as ligangs selective of the dopamine d3 receptor | |
| AU2003207808A1 (en) | Peroxisome proliferator activated receptor modulators | |
| ES2165410T3 (es) | Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen. | |
| WO2008146917A1 (ja) | リンコマイシン誘導体及びこれを有効成分とする抗菌剤 | |
| CA2490152A1 (en) | Oxazole derivatives and their use as insulin sensitizers | |
| CA2314541A1 (fr) | Utilisation de l'acide 4,6-dimethoxy-indole 2-carboxylique ou de ses derives pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute | |
| TH93950B (th) | อนุพันธ์ 1,4-เบนไซโธอีพีน 1,1- ไดออกไซด์ชนิดใหม่ ที่แทนที่โดยเบนซิลแรดิคัล, วิธีสำหรับการเตรียมสารนั้น, เภสัชภัณฑ์ซึ่งประกอบรวมด้วยสารประกอบเหล่านี้และการใช้สารนั้น | |
| IT1302700B1 (it) | Procedimento per la preparazione di un derivato dell'isobenzofurano | |
| WO2003063852A1 (fr) | Agent therapeutique pour incontinence urinaire | |
| YU89903A (sh) | Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa | |
| TH71078A (th) | อนุพันธ์ซับสทิทิวเทด 3-(เบนโซอิลยูริไอโด)ไธโอฟีน, กรรมวิธีสำหรับการเตรียมอนุพันธ์เหล่านี้ และการใช้อนุพันธ์เหล่านี้ |